Blog

Oct 22, 2024

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study | MIRA Stock News

MIRA Pharmaceuticals (NASDAQ:MIRA) announces that its novel oral ketamine analog, Ketamir-2, outperforms FDA-approved neuropathic pain treatments Gabapentin and Pregabalin in preclinical studies. Key

MIRA Pharmaceuticals (NASDAQ:MIRA) announces that its novel oral ketamine analog, Ketamir-2, outperforms FDA-approved neuropathic pain treatments Gabapentin and Pregabalin in preclinical studies. Key findings show Ketamir-2 provided up to 112% more effective results than Pregabalin and 70% greater relief than Gabapentin at higher doses by Day 22 in female rats.

Ketamir-2 offers advantages over current treatments, including being non-habit forming and potentially avoiding sedation and cognitive impairment. MIRA is preparing to submit an Investigational New Drug (IND) application by year-end, with Phase 1 clinical trials scheduled for Q1 2025 and Phase 2 trials in Q4 2025. The company is also exploring Ketamir-2's potential for PTSD treatment and pursuing government grants to accelerate development.

MIRA Pharmaceuticals (NASDAQ:MIRA) annuncia che il suo nuovo analogico orale della ketamina, Ketamir-2, supera i trattamenti approvati dalla FDA per il dolore neuropatico, Gabapentino e Pregabalin, negli studi preclinici. I risultati principali mostrano che Ketamir-2 ha fornito fino a 112% di risultati più efficaci rispetto al Pregabalin e 70% di maggiore sollievo rispetto al Gabapentino a dosi più elevate entro il giorno 22 in ratti femmina.

Ketamir-2 offre vantaggi rispetto ai trattamenti attuali, inclusa la sua natura non abituale e la potenziale possibilità di evitare sedazione e compromissione cognitiva. MIRA sta preparando la presentazione di un Investigational New Drug (IND) entro fine anno, con trials clinici di Fase 1 programmati per il primo trimestre del 2025 e trials di Fase 2 nel quarto trimestre del 2025. L'azienda sta anche esplorando il potenziale di Ketamir-2 per il trattamento del PTSD e perseguendo sovvenzioni governative per accelerare lo sviluppo.

MIRA Pharmaceuticals (NASDAQ:MIRA) anuncia que su nuevo análogo oral de ketamina, Ketamir-2, supera los tratamientos aprobados por la FDA para el dolor neuropático, Gabapentin y Pregabalin, en estudios preclínicos. Los hallazgos clave muestran que Ketamir-2 proporcionó hasta 112% de resultados más efectivos que el Pregabalin y 70% más de alivio que el Gabapentin a dosis más altas para el día 22 en ratas hembras.

Ketamir-2 ofrece ventajas sobre los tratamientos actuales, incluidas su naturaleza no adictiva y la posibilidad de evitar sedación y deterioro cognitivo. MIRA está preparando su solicitud de nuevo fármaco en investigación (IND) para fin de año, con ensayos clínicos de Fase 1 programados para el primer trimestre de 2025 y ensayos de Fase 2 en el cuarto trimestre de 2025. La empresa también está explorando el potencial de Ketamir-2 para el tratamiento del PTSD y buscando subvenciones gubernamentales para acelerar el desarrollo.

MIRA 제약 (NASDAQ:MIRA)는 자사의 새로운 경구용 케타민 유사체인 Ketamir-2가 FDA 승인 신경병증 통증 치료제인 가바پ렌틴(Gabapentin)과 프리가발린(Pregabalin)을 사전 연구에서 능가한다고 발표했습니다. 주요 발견은 Ketamir-2가 프리가발린보다 112% 더 효과적인 결과를 제공하고 가바펜틴보다 70% 더 큰 완화를 제공했음을 보여줍니다. 이는 22일째에 높은 용량에서 확인된 결과입니다.

Ketamir-2는 현재 치료에 비해 습관성이 없고 잠재적으로 진정 작용과 인지 장애를 피할 수 있는 장점이 있습니다. MIRA는 연말까지 임상 시험 신청서(IND)를 제출할 준비를 하고 있으며, 1상 임상 시험이 2025년 1분기로 예정되어 있고 2상 시험은 2025년 4분기로 예정되어 있습니다. 또한 이 회사는 Ketamir-2가 PTSD 치료에 대한 잠재력을 탐색하고 개발을 가속화하기 위한 정부 보조금을 추구하고 있습니다.

MIRA Pharmaceuticals (NASDAQ:MIRA) annonce que son nouvel analogue oral de la kétamine, Ketamir-2, surpasse les traitements approuvés par la FDA pour la douleur neuropathique, Gabapentin et Pregabalin, dans les études précliniques. Les principales conclusions montrent que Ketamir-2 a présenté jusqu'à 112% de résultats plus efficaces que le Pregabalin et 70% de soulagement en plus que le Gabapentin à des doses plus élevées au jour 22 chez des rates.

Ketamir-2 présente des avantages par rapport aux traitements actuels, notamment le fait d'être non addictif et de pouvoir éviter la sédation et le déclin cognitif. MIRA se prépare à soumettre une demande de médicament expérimental (IND) d'ici la fin de l'année, avec des essais cliniques de Phase 1 prévus pour le T1 2025 et des essais de Phase 2 au T4 2025. L'entreprise explore également le potentiel de Ketamir-2 pour le traitement du PTSD et recherche des subventions gouvernementales pour accélérer le développement.

MIRA Pharmaceuticals (NASDAQ:MIRA) gibt bekannt, dass sein neuartiges orales Ketaminanalog Ketamir-2 in präklinischen Studien die von der FDA genehmigten Behandlungen von neuropathischen Schmerzen, Gabapentin und Pregabalin, übertrifft. Wichtige Erkenntnisse zeigen, dass Ketamir-2 bis zu 112% effektivere Ergebnisse als Pregabalin und 70% mehr Linderung als Gabapentin bei höheren Dosen am Tag 22 bei weiblichen Ratten lieferte.

Ketamir-2 bietet Vorteile gegenüber den aktuellen Behandlungen, darunter, dass es nicht süchtig machend ist und möglicherweise Sedierung sowie kognitive Beeinträchtigungen vermeidet. MIRA bereitet die Einreichung eines Investigational New Drug (IND)-Antrags bis zum Jahresende vor, mit Phase-1-Studien, die für das erste Quartal 2025 geplant sind und Phase-2-Studien im vierten Quartal 2025. Das Unternehmen erkundet auch das Potenzial von Ketamir-2 für die PTSD-Behandlung und strebt Regierungsstipendien an, um die Entwicklung zu beschleunigen.

The preclinical study results for Ketamir-2 are highly promising, showing superior efficacy compared to established treatments like Gabapentin and Pregabalin. With 112% more effective results than Pregabalin and 70% greater relief than Gabapentin at higher doses, Ketamir-2 positions itself as a potential game-changer in neuropathic pain treatment.

The non-habit forming nature of Ketamir-2 addresses a critical gap in current treatments, especially considering the controlled substance status of Pregabalin. This could lead to significant market penetration if these results translate to human trials. The potential for fewer cognitive side effects further enhances its appeal.

MIRA's expansion into PTSD treatment and pursuit of government grants demonstrates strategic diversification. The planned IND submission and clinical trial timeline suggest a well-structured development path. However, investors should note that success in preclinical stages doesn't guarantee clinical trial success or FDA approval.

The market potential for Ketamir-2 is substantial, given the projected growth of the neuropathic pain treatment market. With Gabapentin expected to reach $4.95 billion by 2033 and Pregabalin forecasted at $2.2 billion by 2032, there's a clear demand for effective treatments. Ketamir-2's superior efficacy and potentially improved side effect profile could disrupt this market significantly.

MIRA's expansion into PTSD treatment opens up additional market opportunities, especially with increased focus on mental health. The pursuit of FDA breakthrough designation for chemotherapy-induced neuropathy could accelerate market entry and provide a competitive edge. However, as a pre-clinical stage company with a market cap of just $17.89 million, MIRA faces significant challenges in bringing Ketamir-2 to market, including funding requirements and regulatory hurdles.

MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica). Ketamir-2, a non-opioid, offers tremendous promise for patients seeking better solutions for neuropathic pain without the habit-forming risks or debilitating side effects associated with existing medications.

Key Study Findings:

The latest preclinical study, conducted using a nerve ligation-induced neuropathy model in female rats, demonstrated that low doses of oral Ketamir-2 provided significant pain relief by Day 15. By Day 22, Ketamir-2 achieved up to 112% more effective results than Pregabalin and 70% greater relief than Gabapentin at higher doses. These findings build on prior studies in male rats, where Ketamir-2 fully reversed neuropathic pain, while oral ketamine showed no effect. This consistent efficacy across different models further highlights Ketamir-2's potential to deliver superior, effective relief through the oral route, positioning it as a promising alternative to current treatments.

Limitations of Current FDA-Approved Treatments and the Need for Innovation:

Neuropathic pain is a growing global health concern, with increasing prevalence linked to conditions like diabetes, chemotherapy-induced nerve damage, and post-herpetic neuralgia. The demand for effective pain management is reflected in the large and expanding market for treatments like Gabapentin (Neurontin) and Pregabalin (Lyrica). Gabapentin is expected to reach $4.95 billion by 2033, growing at a 6.12% CAGR (source). Similarly, the pregabalin market is forecast to grow to $2.2 billion by 2032, driven by the need for chronic pain relief (source).

Despite their widespread use, these drugs come with significant side effects that limit their long-term effectiveness:

Gabapentin: Long-term use can cause drowsiness, dizziness, cognitive impairment, and weight gain, along with the potential for misuse and withdrawal upon discontinuation (source).

Pregabalin: As a controlled substance, Pregabalin carries a risk of dependence. Patients frequently report weight gain, edema, and cognitive issues, and withdrawal symptoms are common when the drug is stopped (source).

Ketamir-2: A Safer, More Effective Alternative:

Ketamir-2 offers several key advantages over current treatments:

Non-Habit Forming: Unlike Pregabalin, Ketamir-2 carries no known risk of dependence, making it safer for long-term use.

Superior Pain Relief: The preclinical data shows that Ketamir-2 offers better efficacy than Pregabalin and better efficacy than Gabapentin.

Fewer Cognitive Side Effects: With the potential to avoid sedation and cognitive impairment, Ketamir-2 offers an improved quality of life compared to currently available treatments.

Expanding Ketamir-2's Potential Beyond Neuropathic Pain:

MIRA is actively preparing to launch preclinical trials for post-traumatic stress disorder (PTSD), recognizing the urgent need for non-addictive treatments for PTSD. The growing mental health crisis highlights the need for effective alternatives to existing PTSD medications, and Ketamir-2 has the potential to fill that gap.

The company is also actively pursuing government grants for PTSD and other indications, capitalizing on the increased public focus and funding initiatives aimed at mental health treatment. These grants could help accelerate the development and delivery of Ketamir-2 to patients suffering from PTSD, depression, and other neuropsychiatric conditions.

Next Steps:

MIRA is on track to submit an Investigational New Drug (IND) application for Ketamir-2 by the end of this year and is currently preparing for Phase 1 clinical trials scheduled to begin in the first quarter of 2025. The company aims to start Phase 2 trials in the last quarter of 2025, allowing for the first signs of human efficacy by the end of that year.

As part of these preparations, MIRA is pursuing scientific publications to share progress and insights with the broader medical community. Ongoing preclinical studies are evaluating Ketamir-2's impact on chemotherapy-induced neuropathy, a condition that, if proven effective, could qualify the drug for FDA breakthrough designation, potentially shortening the regulatory timeline. The company is also conducting further studies for diabetic neuropathy, expanding the therapeutic potential of Ketamir-2.

"We are fully committed to bringing this breakthrough drug to patients as quickly as possible while backing everything we do with strong science," said Erez Aminov, Chairman and CEO of MIRA Pharmaceuticals. "Ketamir-2 has the potential not only to address neuropathic pain but also to make a significant impact in the treatment of PTSD and depression. Our goal is to ensure that those who need it most have access to this innovative treatment as soon as possible."

"The very encouraging preclinical results obtained to date are truly remarkable, and we are excited about the strong promise of Ketamir-2 as we smoothly advance it through development," added Dr. Angel, Chief Scientific Advisor at MIRA Pharmaceuticals.

About MIRA Pharmaceuticals, Inc

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).

MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.

The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.

Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at http://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya [email protected](786) 432-9792

SOURCE: Mira Pharmaceuticals, Inc.